Thursday’s essay covered Roche's bet on an unproven Chinese cancer antibody.
Two days after that deal closed, GSK signed one of its own: $110 million upfront for HMPL-A830, an experimental cancer therapy from Hong Kong-listed HUTCHMED, with a total value that could reach $1.295 billion if every milestone lands.
That's two major licensing deals in a single week for Chinese-invented cancer drugs. If that were the whole story, it would still be worth a headline.
It isn't the whole story.
The same appetite for Chinese intellectual property that's reshaping Pharma is showing up in batteries and telecom patents too.
Different industries, different molecules and machines, but the same underlying shift: real money changing hands for what China now knows, not just what China can build.
The Spending Behind the Deals